Innovative Diagnostic Platform Rosetta Genomics has developed a proprietary microRNA-based diagnostic platform that supports the development and commercialization of molecular tests in oncology and pathology, providing opportunities to expand into new cancer and disease types.

Recent Acquisition Activity Following its acquisition by Genoptix Inc. in 2017, there may be potential for upselling and cross-selling new genomic diagnostic solutions to existing clients within the oncology diagnostics market.

Expanding Test Portfolio With its established tests like RosettaGX Reveal and Cancer Origin, there are potential sales openings to promote adjunct testing services such as core FISH, IHC, and PCR-based diagnostics in hospitals and pathology labs.

Market Growth Opportunity The company operates in a growing segment of molecular diagnostics with revenues estimated between $10M and $25M, indicating a solid presence but room for expansion into larger healthcare facilities and international markets.

Technological Capabilities Utilizing advanced bioinformatics combined with state-of-the-art laboratory processes, Rosetta Genomics offers an attractive proposition for clinics and labs seeking cutting-edge, validated microRNA and genetic testing solutions.